https://pharminent.com/81923-2/ 2026-06-15T18:39:12Z Pharminent en 2026-06-15T18:39:08Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-15-2026/ 2026-06-15T16:53:19Z Pharminent en Strategic News Watch • June 15, 2026 2026-06-15T16:53:17Z Blog https://pharminent.com/eisai-claims-uk-grant-to-expand-manufacturing-site/ 2026-06-15T14:15:47Z Pharminent en Eisai claims UK grant to expand manufacturing site 2026-06-15T12:19:37Z Blog https://pharminent.com/key-pipeline-drug-for-lundbeck-delivers-in-cushing-syndrome/ 2026-06-15T14:46:08Z Pharminent en Key pipeline drug for Lundbeck delivers in Cushing syndrome 2026-06-15T11:37:08Z Blog https://pharminent.com/rhythms-obesity-drug-scores-better-than-expected-weight-loss-in-rare-genetic-disease/ 2026-06-15T14:15:23Z Pharminent en Rhythm's obesity drug scores 'better than expected' weight loss in rare genetic disease 2026-06-15T11:24:33Z Blog https://pharminent.com/lilly-sees-quick-return-on-2-3b-ajax-buy-as-blood-cancer-drug-shows-early-efficacy/ 2026-06-15T15:31:15Z Pharminent en Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy 2026-06-15T10:51:02Z Blog https://pharminent.com/data-could-move-jjs-talvey-earlier-in-myeloma-therapy/ 2026-06-15T14:46:51Z Pharminent en Data could move J&J's Talvey earlier in myeloma therapy 2026-06-15T10:12:18Z Blog https://pharminent.com/fda-clears-msds-keytruda-combo-plus-welireg-for-ccrcc-treatment/ 2026-06-15T14:15:00Z Pharminent en FDA clears MSD's Keytruda combo plus Welireg for ccRCC treatment 2026-06-15T08:55:49Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-june-13-2026/ 2026-06-13T19:03:54Z Pharminent en Week in Review • INTELLIGENCE BRIEF • June 13, 2026 2026-06-13T19:03:51Z Blog